Literature DB >> 11915031

alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study.

Masayoshi Ijichi1, Tadatoshi Takayama, Masayuki Matsumura, Yasushi Shiratori, Masao Omata, Masatoshi Makuuchi.   

Abstract

alpha-fetoprotein (AFP) messenger RNA (mRNA) has been proposed as a marker of hepatocellular carcinoma (HCC) cells disseminated into the circulation, but its clinical significance remains controversial. We prospectively assessed the prognostic value of AFP mRNA in patients undergoing curative hepatic resection for HCC. Peripheral blood samples were taken from 87 patients before and after surgery to determine the presence of AFP mRNA by use of a reverse-transcription polymerase chain reaction. A primary endpoint was recurrence-free interval. AFP mRNA was detectable preoperatively in 31 patients (36%) and postoperatively in 30 patients (34%). With a median follow-up period of 28 months (range, 3-41 months), HCC recurred in 46 patients (53%). Among 4 groups separated according to preoperative and postoperative AFP mRNA status, patients with consistent positivity of AFP mRNA showed the highest recurrence rate (85%) and trend to distant or multiple recurrence. The recurrence-free interval was significantly shorter in patients with postoperative positivity of AFP mRNA than in those without (53% [95% CI, 36-71] vs. 88% [95% CI, 79-96] at 1 year, 37% [95% CI, 17-57] vs. 60% [95% CI, 46-75] at 2 years; P =.014), whereas the preoperative positivity of AFP mRNA provided no significance (P =.100). Cox's proportional-hazards model identified the postoperative positivity of AFP mRNA as an independent prognostic factor for HCC recurrence (relative risk, 2.33; 95% CI, 1.26-4.34; P =.007). In conclusion, postsurgical recurrence of HCC can be predicted by detecting AFP mRNA-expressing cells in peripheral blood.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11915031     DOI: 10.1053/jhep.2002.32100

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

1.  Construction and expression of recombined human AFP eukaryotic expression vector.

Authors:  Li-Wang Zhang; Jun Ren; Liang Zhang; Hong-Mei Zhang; Bin Jin; Bo-Rong Pan; Xiao-Ming Si; Yan-Jun Zhang; Zhong-Hua Wang; Yang-Lin Pan; Stephen M Festein
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

2.  Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma.

Authors:  Umberto Cillo; Alessandro Vitale; Filippo Navaglia; Daniela Basso; Umberto Montin; Marco Bassanello; Francesco D'Amico; Francesco Antonio Ciarleglio; Alberto Brolese; Giacomo Zanus; Vito De Pascale; Mario Plebani; Davide Francesco D'Amico
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

Review 3.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

4.  The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma.

Authors:  Shogo Kobayashi; Akira Tomokuni; Hidenori Takahashi; Hirofumi Akita; Keijiro Sugimura; Norikatsu Miyoshi; Jeong Ho Moon; Masayoshi Yasui; Takeshi Omori; Masayuki Ohue; Yoshiyuki Fujiwara; Masahiko Yano; Masato Sakon
Journal:  Gastrointest Tumors       Date:  2017-02-08

5.  Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood.

Authors:  Osakuni Morimoto; Hiroaki Nagano; Atsushi Miyamoto; Yoshiyuki Fujiwara; Motoi Kondo; Tameyoshi Yamamoto; Hideo Ota; Masato Nakamura; Hiroshi Wada; Bazarragchaa Damdinsuren; Shigeru Marubashi; Keizo Dono; Koji Umeshita; Shoji Nakamori; Masato Sakon; Morito Monden
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

6.  High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma.

Authors:  Keiko Takagi; Tadatoshi Takayama; Hiroki Nagase; Masamichi Moriguchi; Xiaofei Wang; Kaname Hirayanagi; Tsukasa Suzuki; Hiromasa Hasegawa; Takanaga Ochiai; Nobuhisa Yamaguchi; Mitsugu Kochi; Makoto Kimura; Mariko Esumi
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

Review 7.  A decade's studies on metastasis of hepatocellular carcinoma.

Authors:  Zhao-You Tang; Sheng-Long Ye; Yin-Kun Liu; Lun-Xiu Qin; Hui-Chuan Sun; Qin-Hai Ye; Lu Wang; Jian Zhou; Shuang-Jian Qiu; Yan Li; Xue-Ning Ji; Hu Liu; Jing-Ling Xia; Zhi-Quan Wu; Jia Fan; Zeng-Chen Ma; Xin-Da Zhou; Zhi-Ying Lin; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-18       Impact factor: 4.553

8.  Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial-Mesenchymal Transition after Resection.

Authors:  Ting-Jung Wu; Shih-Shin Chang; Chia-Wei Li; Yi-Hsin Hsu; Tse-Ching Chen; Wei-Chen Lee; Chau-Ting Yeh; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2015-12-11       Impact factor: 12.531

Review 9.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

Review 10.  The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).

Authors:  Yoichi Ishizaki; Seiji Kawasaki
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.